Considering that KRAS codon 61 and 146 mutations may also confer resistance to EGFR inhibitors[26-29,93], patients who have metastatic colorectal cancer with KRAS mutation in codon 61 or 146 could receive more tailored management through clinical testing of these additional KRAS codons. This evidence concerns the gene EGFR and metastatic colorectal cancer.